Genmab Announces Financial Results for the First Nine Months of 2017
November 8, 2017; Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2017 Highlights USD 871 million in net sales of DARZALEX® (daratumumab); resulting in royalty income of DKK 707 million DARZALEX approved for relapsed or …